MRNA logo

MRNAModerna Inc

$51.60
$1.96
(3.95%)
Today
Updated: 10:54 AM EDT
EarningsJul 31
Mkt Cap$19.7B
Vol1.15M
News
all
press releases
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
Key PointsParabilis and another recent IPO stock each raised more than Moderna -- which had previously been the biggest biotech IPO...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.
Zacks
News Placeholder
Does Moderna Need to Start Making Money?
Does Moderna Need to Start Making Money...
Yahoo! Finance: News
News Placeholder
Novavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus
Moderna gains up to $50M from CEPI to advance a Bundibugyo ebolavirus vaccine as the partnership expands amid an ongoing Ebola outbreak.
Zacks
News Placeholder
Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls
Moderna reports five-year melanoma trial results with Merck and expands its Ebola vaccine partnership with CEPI, but MRNA stock is down.read more...
Benzinga
News Placeholder
Moderna Snags $50 Million Ebola Vax Contract
false
Zero Hedge
News Placeholder
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?
VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.
Zacks
News Placeholder
Healthcare ETFs to Buy as Eli Lily Steps Into Vaccine Market With $4B Bet
LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.
Zacks
<
1
2
...
>

Advertisement|Remove ads.